COVID-19
Resources

Lantheus Addresses COVID-19

We remain grateful for the work all health care workers and government officials are doing to keep our communities healthy and safe. We send our thoughts and prayers to those affected by COVID-19 and will continue to do our part to keep our teams and our communities safe and to support our customers and the patients they serve.

View the COVID-19 communications from Lantheus

62%

Echoes with DEFINITY® were acquired 62% faster than unenhanced echoes¹

Lantheus Archived Webinar

COVID-19: Clinical Experience with DEFINITY® from
the Front Line in NYC

A question and answer session with Dr. Martin Goldman, Dr. Lori Croft, and Samantha Buckley, RDCS of Mount Sinai Hospital in New York City. They share their experience treating patients and provide insight into the use of DEFINITY® during the COVID-19 pandemic.

Medical Society Resources

American Society of Echocardiography Coronavirus (COVID-19) Resources

LEARN MORE

American College of Cardiology COVID-19 Hub

LEARN MORE

References:

Sperling D, Lai AC, Bienstock SW, et al. Echocardiography in the time of Covid-19: ultrasound enhancing agents save time and augment diagnostic information. Int J Cardiol. 2022;346:100-102. doi:10.1016/j.ijcard.2021.11.040

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

INDICATIONS

DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

CONTRAINDICATIONS

DEFINITY® is contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG) [see Warnings and Precautions (5.2) and Description (11)].

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

In postmarketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren and PEG-containing microsphere administration [see Adverse Reactions (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions and/or with pre-existing PEG hypersensitivity [see Adverse Reactions (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying conditions.

Patients with sickle cell disease may be at higher risk of painful crisis and DEFINITY® should be administered with caution.

Please see accompanying full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Customer Service 1.800.299.3431

BACK TO
TOP

COVID-19Resources

Lantheus Addresses COVID-19

Echoes with DEFINITY® were acquired 62% faster than unenhanced echoes1

Lantheus Archived Webinar

Medical Society Resources

INDICATIONS

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

COVID-19
Resources

Echoes with DEFINITY® were acquired 62% faster than unenhanced echoes¹